HHS’ Proposed “Action Plan” On Adverse Events
This article was originally published in RPM Report
Executive Summary
Here is the “Conclusion & Next Steps” section for HHS’ draft National Action Plan for Adverse Drug Event Prevention
. The report focuses on three pharmaceutical classes—opioids, antidiabetics and anticoagulants—and catalogs HHS activities to control and reduce adverse reactions.
You may also be interested in...
Improving Drug Safety – Without FDA: HHS Adverse Event Report Focuses On Other Agencies
HHS is declaring a priority of reducing the burden of adverse events associated with three large classes of drugs: opioids, antidiabetics, and anticoagulants. And, at least in its draft action plan, FDA is not the central actor.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.